Structure Therapeutics, Inc. (GPCR)
53.77
-0.48
(-0.88%)
USD |
NASDAQ |
Apr 16, 15:01
Structure Therapeutics Research and Development Expense (Quarterly) : 68.99M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly & Co. | 3.802B |
| Viking Therapeutics, Inc. | 153.46M |
| Novo Nordisk A/S | 2.283B |
| Revolution Medicines, Inc. | 292.61M |
| Kymera Therapeutics, Inc. | 81.80M |